The multifunctional anti-inflammatory drugs used in the therapy of alzheimer's disease

Current Medicinal Chemistry

Volumn 20, Issue 20, 2013, Pages 2583-2588

  Shi, S ^a   Wang, Z ^a   Qiao, Z ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Alzheimer's disease; Anti inflammatory drugs; Microglia; MTDL; NSAIDs; Polyphenols

Indexed keywords

AMYLOID BETA PROTEIN; FLAVONOID; IBUPROFEN; LUTEOLIN; NONSTEROID ANTIINFLAMMATORY AGENT; POLYPHENOL; RESVERATROL; THIOCTIC ACID;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; MICROGLIA; NONHUMAN;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTI-INFLAMMATORY AGENTS; HUMANS; MICROGLIA; POLYPHENOLS;

EID: 84877975754     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320200006     Document Type: Article

References (74)

1. Iqbal K.; del C Alonso A.; Chen S.; Chohan M. O.; El-Akkad E.; Gong C. X.; Khatoon S.; Li B.; Liu F.; Rahman A. Tau pathology in Alzheimer disease and other tauopathies. BBA-Mol. Basis Dis. 2005 1739 (2-3) 198-210. (Pubitemid 40018538)
2. Frank-Cannon T. C.; Alto L. T.; McAlpine F. E.; Tansey M. G. Does neuroinflammation fan the flame in neurodegenerative diseases. Mol. Neurodegener. 2009 4 47.
3. McGEER P. L.; McGEER E. G. Inflammation and the degenerative diseases of aging. Ann. NY. Acad. Sci. 2004 1035 (1) 104-116.
4. Lawson L.; Perry V.; Dri P.; Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990 39 (1) 151-170.
5. Kreutzberg G. W. Microglia: A sensor for pathological events in the CNS. Trends Neurosci. 1996 19 (8) 312-318. (Pubitemid 26349059)
6. Elkabes S.; DiCicco-Bloom E. M.; Black I. B. Brain microglia/macrophages express neurotrophins that selectively regulate microglial proliferation and function. J. Neurosci. 1996 16 (8) 2508-2521. (Pubitemid 26122673)
7. Laurenzi M.; Arcuri C.; Rossi R.; Marconi P.; Bocchini V. Effects of microenvironment on morphology and function of the microglial cell line BV-2. Neurochem. Res. 2001 26 (11) 1209-1216. (Pubitemid 34171691)
8. Block M. L.; Hong J.-S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog.Neurobiol. 2005 76 (2) 77-98. (Pubitemid 41242883)
9. Marin-Teva J. L.; Dusart I.; Colin C.; Gervais A.; Van Rooijen N.; Mallat M. Microglia promote the death of developing Purkinje cells. Neuron 2004 41 (4) 535-547. (Pubitemid 38253066)
10. Aarum J.; Sandberg K.; Haeberlein S. L. B.; Persson M. A. A. Migration and differentiation of neural precursor cells can be directed by microglia. P. Natl. Acad. Sci. USA. 2003 100 (26) 15983.
11. Fourgeaud L.; Boulanger L. M. Synapse remodeling compliments of the complement system. Cell 2007 131 (6) 1034-1036. (Pubitemid 350245399)
12. Polazzi E.; Monti B. Microglia and neuroprotection: from in vitro studies to therapeutic applications. Prog.Neurobiol. 2010 92 (3) 293-315.
13. Meyer-Luehmann M.; Spires-Jones T. L.; Prada C.; Garcia-Alloza M.; De Calignon A.; Rozkalne A.; Koenigsknecht-Talboo J.; Holtzman D. M.; Bacskai B. J.; Hyman B. T. Rapid appearance and local toxicity of amyloid- plaques in a mouse model of Alzheimer's disease. Nature 2008 451 (7179) 720-724. (Pubitemid 351220570)
14. Barger S. W.; Harmon A. D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997 388 (6645) 878-881. (Pubitemid 27377060)
15. Broussard G. J.; Mytar J.; Li R.-c.; Klapstein G. J. The role of inflammatory processes in Alzheimer's disease. Inflammo pharmacology 2012 1-18.
16. McGeer E. G.; McGeer P. L. Inflammatory processes in Alzheimer's disease. Prog. Neuro-Psychoph. 2003 27 (5) 741-749. (Pubitemid 36966754)
17. Conejero-Goldberg C.; Davies P.; Ulloa L. Alpha7 nicotinic acetylcholine receptor: A link between inflammation and neurodegeneration. Neurosci. Biobehav. R. 2008 32 (4) 693-706.
18. Holmes C.; Cunningham C.; Zotova E.; Woolford J.; Dean C.; Kerr S.; Culliford D.; Perry V. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009 73(10) 768-774.
19. Nicoll J. A. R.; Wilkinson D.; Holmes C.; Steart P.; Markham H.; Weller R. O. Neuropathology of human Alzheimer disease after immunization with amyloid- peptide: A case report. Nat. Med. 2003 9 (4) 448-452. (Pubitemid 36460079)
20. Hardy J.; Selkoe D. J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002 297 (5580) 353-356. (Pubitemid 34790756)
21. Broussard G. J.; Mytar J.; Li R. C.; Klapstein G. J. The role of inflammatory processes in Alzheimer's disease. Inflammo pharmacology 2012 20 (3) 109-126.
22. Sabbagh M.; Cummings J. Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC neurol. 2011 11 (1) 21.
23. Alvarez A.; Alarcón R.; Opazo C.; Campos E. O.; Muñoz F. J.; Calderón F. H.; Dajas F.; Gentry M. K.; Doctor B. P.; De Mello F. G.; Inestrosa N. C. Stable complexes involving acetylcholine sterase and amyloid- peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J. Neurosci. 1998 18 (9) 3213-3223. (Pubitemid 28186014)
24. Broe G.; Henderson A.; Creasey H.; McCusker E.; Korten A.; Jorm A.; Longley W.; Anthony J. A casecontrol study of Alzheimer's disease in Australia. Neurology 1990 40 (11) 1698-1698.
25. Li G.; Shen Y.; Li Y.; Chen C.; Zhau Y.; Silverman J. A casecontrol study of Alzheimer's disease in China. Neurology 1992 42 (8) 1481-1481.
26. McGeer P. L.; Mcgeer E.; Rogers J.; Sibley J. Anti-inflammatory drugs and Alzheimer disease. Lancet 1990 335 (8696) 1037. (Pubitemid 20148621)
27. Szekely C. A.; Thorne J. E.; Zandi P. P.; Ek M.; Messias E.; Breitner J. C. S.; Goodman S. N. Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: A systematic review. Neuroepidemiology 2004 23 (4) 159-169. (Pubitemid 38980441)
28. Yip A. G.; Green R. C.; Huyck M.; Cupples L. A.; Farrer L. A. Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. B.M.C. Geriatr. 2005 5 (1) 2.
29. Kukar T.; Prescott S.; Eriksen J. L.; Holloway V.; Murphy M. P.; Koo E. H.; Golde T. E.; Nicolle M. M. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. B.M.C. Neurosci. 2007 8 (1) 54.
30. Kotilinek L. A.; Westerman M. A.; Wang Q.; Panizzon K.; Lim G. P.; Simonyi A.; Lesne S.; Falinska A.; Younkin L. H.; Younkin S. G. Cyclooxygenase-2 inhibition improves amyloid-mediated suppression of memory and synaptic plasticity. Brain 2008 131 (3) 651-664. (Pubitemid 351294724)
31. Townsend K. P.; Praticó D. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. FASEB. J. 2005 19 (12) 1592-1601. (Pubitemid 41429517)
32. Dokmeci D. Ibuprofen and Alzheimer's disease. Folia medica 2004 46 (2) 5.
33. Casper D.; Yaparpalvi U.; Rempel N.; Werner P. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci. Lett. 2000 289 (3) 201-204. (Pubitemid 30657973)
34. Chang W. E.; Takeda T.; Raman E. P.; Klimov D. K. Molecular dynamics simulations of anti-Aggregation effect of ibuprofen. Biophys. J. 2010 98 (11) 2662-2670.
35. Kony D. Explicit-Solvent Molecular Dynamics Simulations of the Polysaccharide Schizophyllan in Water. Biophys. J. 2007 93 (2) 442-455. (Pubitemid 47057811)
36. Lim G.; Yang F.; Chu T.; Gahtan E.; Ubeda O.; Beech W.; Overmier J.; Hsiao-Ashec K.; Frautschy S.; Cole G. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging 2001 22 (6) 983-991. (Pubitemid 34066567)
37. Lim G.; Yang F.; Chu T.; Chen P.; Beech W.; Teter B.; Tran T.; Ubeda O.; Ashe K. H.; Frautschy S. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 2000 20 (15) 5709-5714. (Pubitemid 30636898)
38. Morihara T.; Teter B.; Yang F.; Lim G. P.; Boudinot S.; Boudinot F. D.; Frautschy S. A.; Cole G. M. Ibuprofen suppresses interleukin-I induction of pro-Amyloidogenic 1-Antichymotrypsin to ameliorate -Amyloid (a) pathology in Alzheimer's models. Neuropsycho pharmacology 2005 30 (6) 1111-1120. (Pubitemid 40720969)
39. Zhou Y.; Su Y.; Li B.; Liu F.; Ryder J. W.; Wu X.; Gonzalez-DeWhitt P. A.; Gelfanova V.; Hale J. E.; May P. C.; Paul S. H.; Ni B. Nonsteroidal Anti-Inflammatpry Drugs Can Lower Amyloidogenic A 42 by Inhibiting Rho. Science 2003 302 (5648) 1215-1217. (Pubitemid 37421027)
40. Dill J.; Patel A. R.; Yang X. L.; Bachoo R.; Powell C. M.; Li S. A molecular mechanism for ibuprofen-mediated RhoA inhibition in neurons. J. Neurosci. 2010 30 (3) 963-972.
41. McKee A. C.; Carreras I.; Hossain L.; Ryu H.; Klein W. L.; Oddo S.; LaFerla F. M.; Jenkins B. G.; Kowall N. W.; Dedeoglu A. Ibuprofen reduces A [beta] hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res. 2008 1207 225-236.
42. Leopoldini M.; Russo N.; Toscano M. The molecular basis of working mechanism of natural polyphenolic antioxidants. Food Chem. 2011 125 (2) 288-306.
43. Gomes A.; Fernandes E.; Lima J. L. F. C.; Mira L.; Corvo M. L. Molecular mechanisms of anti-inflammatory activity mediated by flavonoids. Curr. Med. Chem. 2008 15 (16) 1586-1605.
44. Funakoshi-Tago M.; Nakamura K.; Tago K.; Mashino T.; Kasahara T. Anti-inflammatory activity of structurally related flavonoids Apigenin Luteolin and Fisetin. Int. Immuno pharmacol. 2011 11 (9) 1150-1159.
45. Youdim K. A.; Joseph J. A. A possible emerging role of phytochemicals in improving age-related neurological dysfunc tions: A multiplicity of effects. Free Radical Bio. Med. 2001 30 (6) 583-594. (Pubitemid 32280784)
46. Vauzour D.; Vafeiadou K.; Rodriguez-Mateos A.; Rendeiro C.; Spencer J. P. E. The neuroprotective potential of flavonoids: A multiplicity of effects. Genes Nutr. 2008 3 (3) 115-126.
47. Joseph J. A.; Shukitt-Hale B.; Denisova N. A.; Bielinski D.; Martin A.; McEwen J. J.; Bickford P. C. Reversals of age-related declines in neuronal signal transduction cognitive and motor behavioral deficits with blueberry spinach or strawberry dietary supplementation. J. nNeurosci. 1999 19 (18) 8114-8121. (Pubitemid 30225807)
48. Spencer J. P. E. The interactions of flavonoids within neuronal signalling pathways. Genes Nutr. 2007 2 (3) 257-273.
49. Bhat N. R.; Zhang P.; Lee J. C.; Hogan E. L. Extracellular signal-regulated kinase and p38 subgroups of mitogen-Activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor- gene expression in endotoxin-stimulated primary glial cultures. J. Neurosci. 1998 18 (5) 1633-1641. (Pubitemid 28103071)
50. Spencer J. P. E.; Vafeiadou K.; Williams R. J.; Vauzour D. Neuroinflammation: Modulation by flavonoids and mechanisms of action. Mol. Aspects Med. 2011.
51. Vafeiadou K.; Vauzour D.; Lee H. Y.; Rodriguez-Mateos A.; Williams R. J.; Spencer J. P. E. The citrus flavanone naringenin inhibits inflammatory signalling in glial cells and protects against neuroinflammatory injury. Arch. Biochem. Biophys. 2009 484 (1) 100-109.
52. Odontuya G.; Hoult J.; Houghton P. Structureactivity relationship for antiinflammatory effect of luteolin and its derived glycosides. Phytother Res. 2005 19 (9) 782-786. (Pubitemid 41571428)
53. Jang S.; Dilger R. N.; Johnson R. W. Luteolin inhibits microglia and alters hippocampal-dependent spatial working memory in aged mice. J. Nutr. 2010 140 (10) 1892-1898.
54. Dirscherl K.; Karlstetter M.; Ebert S.; Kraus D.; Hlawatsch J.; Walczak Y.; Moehle C.; Fuchshofer R.; Langmann T. Luteolin triggers global changes in the microglial transcriptome leading to a unique anti-inflammatory and neuroprotective phenotype. J. Neuroinflammation 2010 7 (1) 3.
55. Kim J. S.; Lee H. J.; Lee M. H.; Kim J.; Jin C.; Ryu J. H. Luteolin inhibits LPS-stimulated inducible nitric oxide synthase expression in BV-2 microglial cells. Planta Med. 2006 72 (1) 65-67.
56. Jang S.; Kelley K. W.; Johnson R. W. Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1. P. Natl. Acad. Sci. 2008 105 (21) 7534.
57. Zhu L. H.; Bi W.; Qi R. B.; Wang H. D.; Wang Z. G.; Zeng Q.; Zhao Y. R.; Lu D. X. Luteolin reduces primary hippocampal neurons death induced by neuroinflammation. Neurol. Res. 2011 33 (9) 927-934.
58. Zhou F.; Chen S.; Xiong J.; Li Y.; Qu L. Luteolin Reduces Zinc-Induced Tau Phosphorylation at Ser262/356 in an ROSDependent Manner in SH-SY5Y Cells. Biol. Trace Elem. Res. 2012 1-7.
59. Gatz S. A.; Wiesmüller L. Take a break-resveratrol in action on DNA. Carcinogenesis 2008 29 (2) 321-332.
60. Savaskan E.; Olivieri G.; Meier F.; Seifritz E.; Wirz-Justice A.; Müller-Spahn F. Red wine ingredient resveratrol protects from -Amyloid neurotoxicity. Gerontology 2003 49 (6) 380-383. (Pubitemid 37465118)
61. Marambaud P.; Zhao H.; Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid- peptides. J. Biol. Chem. 2005 280 (45) 37377.
62. Zhang F.; Liu J.; Shi J. S. Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation. Eur. J. Pharmacol. 2010 636 (1) 1-7.
63. Das S.; Das D. K. Anti-inflammatory responses of resveratrol. Inflamm. Allergy Drug Targets 2007 6 (3) 168-173. (Pubitemid 47455785)
64. Capiralla H.; Vingtdeux V.; Zhao H.; Sankowski R.; AlAbed Y.; Davies P.; Marambaud P. Resveratrol mitigates lipopoly saccharideand Amediated microglial inflammation by inhibiting the TLR4/NFB/STAT signaling cascade. J. Neurochem. 2012.
65. Pisani L.; Catto M.; Leonetti F.; Nicolotti O.; Stefanachi A.; Campagna F.; Carotti A. Targeting monoamine oxidases with multipotent ligands: An emerging strategy in the search of new drugs against neurodegenerative diseases. Curr. Med. Chem. 2011 18 (30) 4568-4587.
66. Liu J. The effects and mechanisms of mitochondrial nutrient -lipoic acid on improving age-Associated mitochondrial and cognitive dysfunction: An overview. Neurochem. Res. 2008 33 (1) 194-203. (Pubitemid 350242787)
67. Maczurek A.; Hager K.; Kenklies M.; Sharman M.; Martins R.; Engel J.; Carlson D. A.; Münch G. Lipoic acid as an antiinflammatory and neuroprotective treatment for Alzheimer's disease. Adv. Drug Deliv. Rev. 2008 60 (13) 1463-1470.
68. Lovell M. A.; Xie C.; Xiong S.; Markesbery W. R. Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J. Alzheimers Dis. 2003 5 (3) 229-240.
69. Zhang L.; Barker J. L.; Chang Y.; Maric D.; Ma W.; Li B.; Rubinow D. R. -Lipoic acid protects rat cortical neurons against cell death induced by amyloid and hydrogen peroxide through the Akt signalling pathway. Neurosci. Lett. 2001 312 (3) 125-128. (Pubitemid 32972139)
70. Hager K.; Marahrens A.; Kenklies M.; Riederer P.; Münch G. Alpha-lipoic acid as a new treatment option for Azheimer type dementia. Arch.Gerontol. Geriat. 2001 32 (3) 275-282. (Pubitemid 32505692)
71. Rosini M.; Simoni E.; Bartolini M.; Tarozzi A.; Matera R.; Milelli A.; Hrelia P.; Andrisano V.; Bolognesi M. L.; Melchiorre C. Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease. Eur. J. Med. Chem. 2011 46 (11) 5435-5442.
72. Rosini M.; Andrisano V.; Bartolini M.; Bolognesi M. L.; Hrelia P.; Minarini A.; Tarozzi A.; Melchiorre C. Rational approach to discover multipotent anti-Alzheimer drugs. J. Med. Chem. 2005 48 (2) 360-363. (Pubitemid 40139781)
73. Sozio P.; D'Aurizio E.; Iannitelli A.; Cataldi A.; Zara S.; Cantalamessa F.; Nasuti C.; Di Stefano A. Ibuprofen and lipoic acid diamides as potential codrugs with neuroprotective activity. Arch. Pharm. (Weinheim) 2010 343 (3) 133-142.
74. Zara S.; Rapino M.; Sozio P.; Di Stefano A.; Nasuti C.; Cataldi A. Ibuprofen and lipoic acid codrug 1 control Alzheimer's disease progression by down-regulating protein kinase C -mediated metalloproteinase 2 and 9 levels in -Amyloid infused Alzheimer's disease rat model. Brain Res. 2011 1412 79-87.